



MARYLAND ACADEMY OF FAMILY PHYSICIANS

ABLE, RESPONSIVE FAMILY PHYSICIANS SERVING THEIR COMMUNITIES

**References for Articles Appearing in the Fall, 2013 Edition of
The Maryland Family Doctor
Theme: Focus on Cardiovascular Medicine**

CVD A Global Epidemic by Joseph W. Zebley, III, M.D.

1. World Health Organization, 2009. Cardiovascular Diseases.
<http://www.who.int/mediacentre/factsheets/fs317/en/index.html>;
http://www.who.int/cardiovascular_diseases/priorities/en/index.html. Accessed June 17, 2010.
[Cited Here...](#)
 2. World Health Organization, 2005. Preventing chronic diseases: a vital investment.
http://www.who.int/chp/chronic_disease_report/contents/en/index.html. Accessed June 17, 2010.
[Cited Here...](#)
 3. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet*. 2006;367(9524):1747-1757.
[Cited Here...](#) | [PubMed](#) | [CrossRef](#)
 4. [Mensah GA](#), [Brown DW](#). National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. GMensah@cdc.gov
 - 5 [Yusuf S](#), [Reddy S](#), [Ounpuu S](#), [Anand S](#). Population Health Research Institute and Division of Cardiology, McMaster University, Hamilton, Ontario, Canada. yusufs@mcmaster.ca
- [△] Myerburg, Robert J. "Cardiac Arrest and Sudden Cardiac Death" in *Heart Disease: A Textbook of Cardiovascular Medicine*, 7th edition. [Philadelphia](#): WB Saunders, 2005.
- 7 [△] <http://poptop.hypermart.net/sudden.html>

□ [^](#) Evangelos C. Rizos, MD, PhD; Evangelia E. Ntzani, MD, PhD; Eftychia Bika, MD; Michael S. Kostapanos, MD; Moses S. Elisaf, MD, PhD, FASA, FRSH (September 2012). "Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events A Systematic Review and Meta-analysis". *JAMA* **308** (10): 1024–1033. [doi:10.1001/2012.jama.11374](https://doi.org/10.1001/2012.jama.11374). [PMID 22968891](https://pubmed.ncbi.nlm.nih.gov/22968891/)

[9](#) Yale University School of Medicine Heart Book

Zaret, Moser and Cohen, Pages 23-25 William Morrow and Co. 1st Edition

10 Centers for Disease Control and Prevention. [Current Cigarette Smoking Among Adults—United States, 2011](#). *Morbidity and Mortality Weekly Report* 2012;61(44):889–94 [accessed 2013 June 5].

11. CDC. Vital signs: prevalence, treatment, and control of hypertension--United States, 1999-2002 and 2005-2008. *MMWR*. 2011;60(4):103-8.

12. National Vital Statistics Reports Volume 61, Number 4 May 8, 2013

13. *J Epidemiol Community Health* 2005;59:427-433 [doi:10.1136/jech.2004.024984](https://doi.org/10.1136/jech.2004.024984)

14. *Circulation*. 2013;127:e663-e828,

Beyond Aspirin: A review of Initial Management in Non-ST Elevation Acute Coronary Syndrome by John T. Duell, M.D., Eric S. Ginsberg, M.D., Christopher deFilippi, M.D.

1. Jneid H, et al. 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2012;126:875-910.

2. Thygesen et al. Third Universal Definition of Myocardial Infarction. *Circulation*. 2012;126:2020-2035

3. Anderson J et al. ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina / Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines. *Circulation*. 2007;116:e148-e304.

4. Mehta SR, et al. Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. *N Engl J Med*. 2010;363;10

5. Wiviott, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndrome. *N Engl J Med*. 2007. 357;20.

6. Wallentin, et al. Ticagrelor vs Clopidogrel in Patients with Acute Coronary Syndromes. *N Engl J Med*. 2009. 361;11.

7. Boersma E et al. Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: A Meta-analysis of All Major Randomized Clinical Trials. *Lancet*. 2002;359:189-198.

8. Giugliano RP, et al. Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes. *N Engl J Med*. 2009;360:21

9. Stone GW et al. Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. *JAMA*. 2007;297:591-602

10. Mehta SR et al. Routine vs. Selective Invasive Strategies in Patients With Acute Coronary Syndromes. *JAMA*. 2005;293:2908-2917.

11. Antman EM et al. The TIMI Risk Score for Unstable Angina/non-ST Elevation MI: A Method for Prognostication and Therapeutic Decision Making. *JAMA*. 2000;284:835-42

12. Montalescot G et al. Immediate vs. Delayed Intervention for Acute Coronary Syndromes. *JAMA*. 2009. 302(9):947-954
13. Mehta SR. Early versus Delayed Invasive Intervention in Acute Coronary Syndromes. *N Engl J Med*. 2009;360:21

New Frontiers in Lipidology: Use of Advanced Lipid Testing by Joseph W. Zebley, III, M.D

1. ↪ Sacks FM, Campos H. Clinical review 163: cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal. *J Clin Endocrinol Metab*. 2003; 88: 4525–4532. [FREE Full Text](#)
2. ↪ Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, Kwiterovich PO Jr. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. *J Am Coll Cardiol*. 2007; 50: 1735–1741. [Abstract/FREE Full Text](#)
3. ↪ Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA. The importance of non-HDL cholesterol reporting in lipid management. *J Clin Lipidol*. 2008; 2: 267–273. [Medline](#)
4. ↪ Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA*. 2001; 285: 2486–2497. [FREE Full Text](#)
5. ↪ Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. *Circulation*. 2002; 106: 388–391. [FREE Full Text](#)
6. ↪ De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancina G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular disease and prevention in clinical practice. *Atherosclerosis*. 2003; 171: 145–155. [CrossRefMedline](#)
7. ↪ McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular S. Canadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. *Can J Cardiol*. 2006; 22: 913–927. [Medline](#)
8. ↪ Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KM. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. *J Intern Med*. 2006; 259: 247–258. [CrossRefMedline](#)
9. ↪ Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. *J Am Coll Cardiol*. 2008; 51: 1512–1524. [FREE Full Text](#)
10. ↪ Rifai N, Warnick GR, Dominiczak MH. *Handbook of Lipoprotein Testing*. 2nd ed. Washington, DC: AACC Press; 2000.
11. ↪ NACB Laboratory Medicine Practice Guidelines. Emerging biomarkers of cardiovascular disease and stroke. Draft version 91906. Available at: http://www.aacc.org/SiteCollectionDocuments/NACB/LMPG/Emerging_Risk_

Factors/NACB_full_guidelines_draft_091906.pdf. Accessed November 28, 2008.

12. ↵ Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy: a review of the evidence. *J Intern Med.* 2006; 259: 493–519. [CrossRefMedline](#)
13. ↵ Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. *J Lipid Res.* 1982; 23: 97–104. [Abstract](#)
14. ↵ Kulkarni KR, Garber DW, Marcovina SM, Segrest JP. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. *J Lipid Res.* 1994; 35: 159–168. [Abstract](#)
15. ↵ Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. *Clin Lab.* 2002; 48: 171–180. [Medline](#)
16. ↵ Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, Siscovick D, Freedman DS, Kronmal R. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. *Arterioscler Thromb Vasc Biol.* 2002; 22: 1175–1180. [Abstract/FREE Full Text](#)
17. ↵ Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. *Clin Lab Med.* 2006; 26: 847–870. [CrossRefMedline](#)
18. ↵ Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. *Am J Cardiol.* 2002; 90: 22i–29i. [Medline](#)
19. ↵ Caulfield MP, Li S, Lee G, Blanche PJ, Salameh WA, Benner WH, Reitz RE, Krauss RM. Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. *Clin Chem.* 2008; 54: 1307–1316. [Abstract/FREE Full Text](#)
20. ↵ Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. *Circulation.* 2002; 106: 1930–1937. [Abstract/FREE Full Text](#)
21. ↵ Witte DR, Taskinen MR, Perttunen-Nio H, Van Tol A, Livingstone S, Colhoun HM. Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis. *J Lipid Res.* 2004; 45: 1069–1076. [Abstract/FREE Full Text](#)
22. ↵ Ensign W, Hill N, Heward CB. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. *Clin Chem.* 2006; 52: 1722–1727. [Abstract/FREE Full Text](#)
23. ↵ Stein EA. Are measurements of LDL particles ready for prime time? *Clin Chem.* 2006; 52: 1643–1644. [FREE Full Text](#)
24. ↵ Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. *JAMA.* 2007; 298: 786–798. [Abstract/FREE Full Text](#)
25. ↵ Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. *J Intern Med.* 2006; 259: 481–492. [CrossRefMedline](#)
26. ↵ Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation.* 2001; 104: 1108–1113. [Abstract/FREE Full Text](#)
27. ↵ Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. *Lancet.* 2003; 361: 777–780. [CrossRefMedline](#)
28. ↵ Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC Jr, O'Leary DH, Saad MF, Tsai MY,

- Sharrett AR. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). *Atherosclerosis*. 2007; 192: 211–217. [CrossRefMedline](#)
29. ↵ El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, Hutten BA, Kastelein JJ, Khaw KT, Boekholdt SM. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. *J Am Coll Cardiol*. 2007; 49: 547–553. [Abstract/FREE Full Text](#)
30. ↵ Cromwell WC, Otvos J, Keyes MJ, Pencina MJ, Sullivan D, Vasani RS, Wilson PWF, D'Agostino RB. LDL particle number and risk for future cardiovascular disease in the Framingham Offspring Study: implications for LDL management. *J Clin Lipidol*. 2007; 1: 583–592. [CrossRefMedline](#)
31. ↵ Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. *Clin Chem Lab Med*. 2004; 42: 1355–1363. [CrossRefMedline](#)
32. ↵ Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. *Circulation*. 2005; 112: 3375–3383. [Abstract/FREE Full Text](#)
33. ↵ Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D'Agostino RB, Vasani RS. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. *JAMA*. 2007; 298: 776–785. [Abstract/FREE Full Text](#)
34. ↵ Mora S, Otvos J, Rifai N, Rosenson R, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. *Circulation*. 2009; 119: 931–939. [Abstract/FREE Full Text](#)
35. ↵ Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. *Am J Cardiol*. 2008; 101: 1003–1008. [CrossRefMedline](#)
36. ↵ Sniderman AD. We must prevent disease, not predict events. *J Am Coll Cardiol*. 2008; 52: 300–301. [FREE Full Text](#)
37. ↵ Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. *Lancet*. 2001; 358: 2026–2033. [CrossRefMedline](#)
38. ↵ McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. *Lancet*. 2008; 372: 224–233. [CrossRefMedline](#)
39. ↵ Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. *JAMA*. 2005; 294: 326–333. [Abstract/FREE Full Text](#)
40. ↵ Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasani RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med*. 2008; 27: 157–172. [CrossRefMedline](#)
41. ↵ Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. *Am J Med*. 2001; 110: 103–110. [CrossRefMedline](#)
42. ↵ Campos H, Arnold KS, Balestra ME, Innerarity TL, Krauss RM. Differences in receptor binding of

- LDL subfractions. *Arterioscler Thromb Vasc Biol.* 1996; 16: 794–801. [Abstract/FREE Full Text](#)
43. ↵ Rudel LL, Parks JS, Hedrick CC, Thomas M, Williford K. Lipoprotein and cholesterol metabolism in diet-induced coronary artery atherosclerosis in primates: role of cholesterol and fatty acids. *Prog Lipid Res.* 1998; 37: 353–370. [CrossRefMedline](#)
 44. ↵ Patsch W, Ostlund R, Kuisk I, Levy R, Schonfeld G. Characterization of lipoprotein in a kindred with familial hypercholesterolemia. *J Lipid Res.* 1982; 23: 1196–1205. [Medline](#)
 45. ↵ Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. *JAMA.* 1996; 276: 882–888. [Abstract/FREE Full Text](#)
 46. ↵ Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. *JAMA.* 1996; 276: 875–881. [Abstract/FREE Full Text](#)
 47. ↵ Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. *Circulation.* 1997; 95: 69–75. [Abstract/FREE Full Text](#)
 48. ↵ Hulthe J, Wiklund O, Bondjers G, Wikstrand J. LDL particle size in relation to intima-media thickness and plaque occurrence in the carotid and femoral arteries in patients with hypercholesterolaemia. *J Intern Med.* 2000; 248: 42–52. [CrossRefMedline](#)
 49. ↵ Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM. Low-density lipoprotein size, pravastatin treatment, and coronary events. *JAMA.* 2001; 286: 1468–1474. [Abstract/FREE Full Text](#)
 50. ↵ Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. *Am J Cardiol.* 2002; 90: 89–94. [CrossRefMedline](#)
 51. ↵ Otvos J, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ. LDL and HDL particle subclasses predict coronary events and are changed favorable by gemfibrozil therapy in the Veterans Affairs HDL Intervention Trial (VA-HIT). *Circulation.* 2006; 113: 1556–1563. [Abstract/FREE Full Text](#)
 52. ↵ Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. *Arterioscler Thromb Vasc Biol.* 1997; 17: 1098–1105. [Abstract/FREE Full Text](#)
 53. ↵ Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. *J Am Coll Cardiol.* 2008; 51: 724–730. [Abstract/FREE Full Text](#)
 54. ↵ Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. *J Am Coll Cardiol.* 2008; 52: 626–632. [Abstract/FREE Full Text](#)
 55. ↵ Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. *Circulation.* 2006; 113: 2335–2362. [FREE Full Text](#)
 56. ↵ Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MSV, Go AS, Harrell FE Jr, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand S-LT, O'Donnell CJ, Smith SC Jr, Wilson PWF; on behalf of the American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. *Circulation.* 2009;119:in press.

Beyond LDL-C in the Prevention and Management of Atherosclerotic Cardiovascular Disease by Gregory S. Pokrywka, M.D., FACP, FNLA, NCMP

- I. ¹ Davidson, M. Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein, Apolipoprotein, or Low-Density Lipoprotein Particle. What Should Clinicians Measure? *JACC* 2012;60(25):2616–7.
- II. ¹ Sachdeva, A, Cannon, C, Deedwania, P, et al. Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines. *Am Heart J* 2009;157:111-7.e2.
- III. ¹ Contois, J, Warnick, GR, and Sniderman, Allan. Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. *Journal of Clinical Lipidology* 2011;5: 264–272.
- IV. ¹ Tabas, I, Williams, K and Boren, B. Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis. *Circulation* 2007;116:1832-1844.
- V. ¹ Nasir, K, Martin, S, and Virani, S. Discordance: Can we capitalize on it to better personalize atherosclerosis treatment? [Atherosclerosis](#). 2013;229(2):504-6
- VI. ¹ Davidson, M, and Ballantyne, C. Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. *Journal of Clinical Lipidology* 2011;5:338–367.
- VII. ¹ Cromwell, W, Otvos, J, Keyes, M, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management. *Journal of Clinical Lipidology* 2007;1:583–592.
- VIII. ¹ Contois JH et al. *Clin Chem*. 2009;55:407-19, Brunzell JD et al. *J Am Coll Cardiol*. 2008;51:1512-24, Jellinger PS et al. *Endocr Pract*. 2012;18(Suppl 1):1-78, Davidson MH et al. *J Clin Lipidol*. 2011;5:338-67.
- IX. ¹ Sniderman, A. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. *Journal of Clinical Lipidology* 2008;2:36–42.
- X. ¹ Sniderman, A, Williams, K, Contois, J, et al. A Meta-Analysis of LDL-C, Non-HDL-C, and apoB as Markers of Cardiovascular Risk. *Circ Cardiovasc Qual Outcomes*. 2011;4:337-345.
- XI. ¹ Rizzo, J, Mallow, P, Waters, H, and Pokrywka, G. Managing to low-density lipoprotein particles compared with low-density lipoprotein cholesterol: A cost-effectiveness analysis. *Journal of Clinical Lipidology*, article in press 2013 doi:10.1016/j.jacl.2013.06.004.
- XII. ¹ Contois J, McConnell J, Sethi A, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. *Clin Chem* 2009;55:407–19.
- XIII. ¹ Master, S, and Rader, D. Beyond LDL Cholesterol in Assessing Cardiovascular Risk: ApoB or LDL-P? *Clinical Chemistry* 2013;59(5) paper in press. (The latest version is at <http://hwmain.clinchem.org/cgi/doi/10.1373/clinchem.2013.203208>.)

It's Not Just a Man's Problem by Sarah Ines Ramirez, M.D.

1. http://www.heart.org/idc/groups/heart-public/@wcm/@sop/@smd/documents/downloadable/ucm_319576.pdf

2. Mosca L, Mochari-Greenberger H, Dolor RJ, Newby LK, Robb KJ. Twelve-year follow-up of American women's awareness of cardiovascular disease risk and barriers to heart health. *Circulation: Cardiovascular Quality Outcomes*. 2010;3:120-7.
3. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. *Circulation*. 2012;125(1):e2–220.
4. <http://www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=21#534762>
5. Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. *Circulation*. 2010;121:2317-2325.
6. Sy F, Bsaraon, J, Zheng H, Singh M, Richina J, Ambrose JA. Frequency of Takotsubo Cardiomyopathy in postmenopausal women presenting with an acute coronary syndrome. *American Journal of Cardiology*. 2013. ePub ahead of print: <http://www.ncbi.nlm.nih.gov/pubmed/23683950>.
7. Lyon AR, Rees PS, Prasad S, Poole-Wilson PA, Harding SE. Stress (takotsubo) cardiomyopathy –a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. *National Clinical Practice Cardiovascular Medicine*. 2008; 5 (1): 22-29.
8. Ueyama, T, Ishikura, F, Matsuda, A, Asanuma T, Ueda K, Ichinose M, Kasamatsu K, Hano T, Akasaka T, Tsuruo Y, Morimoto K, Beppu S. Chronic estrogen supplementation following ovariectomy improves the emotional stress-induced cardiovascular response s by indirect action on the nervous system and by direct action of the heart. *Circulation Journal*. 2007;71(4):565-573.
9. Ibáñez B, Navarro F, Farré J, Marcos-Alberca P, Orejas M, Rabago R, Rey M, Romero J, Iniguez A., Cordoba M. Tako-tsubo transient left ventricular apical ballooning is associated with a left anterior descending coronary artery with a long course along the apical diaphragmatic surface of the left ventricle. *Revista española de cardiología*. 2004;57(3): 209–16.
10. Gianni M, Dentali F, Grandi AM, Sumner G, Hiralai R, Lonn E. Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. *European Heart Journal*. 2006;27:1523-1529.
11. <http://www.uptodate.com/contents/stress-induced-takotsubo-cardiomyopathy>
12. Toth, PP. High-density lipoprotein and cardiovascular risk: Clinician Update. *Circulation*. 2004;109:1809-1812.
13. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. *Journal Cardiovascular Risk*. 1996; 3: 213–219.
14. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA*. 2007;298(3):299-308.

15. Woodard GA, Brooks MM, Barinas-Mitchell E, Mackey RH, Matthews KA, Sutton-Tyrrell K. Lipids, menopause, and early atherosclerosis in SWAN Heart Women: Menopausal transition and lipids. *Menopause*. 2001;18(4):376-284
16. Dayspring TD. Understanding hypertriglyceridemia in women: clinical impact and management with prescription omega-3-acid ethyl esters. *International Journal of Womens Health*. 2011; 3:87-97.
17. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, Nathan DM, Manson JE. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20year of follow-up. *Archives of Internal Medicine*. 2001;161(14):1717-1723.
18. Dale AC, Nilsen TI, Vatten L, Midthjell K, Wiseth R. Diabetes mellitus and risk of fatal ischaemic heart disease by gender: 18 years follow-up of 74914 individuals in the HUNT 1 Study. *European Heart Journal*. 2007; 27:2924-2929.
19. Cardiovascular disease: Women's number one health threat. http://www.heart.org/idc/groups/heart-public/@wcm/@adv/documents/downloadable/ucm_302256.
20. Sandhu RK, Jimenez MC, Chiuve SE, Fitzgerald K, Kenfield SA, Tedrow UB, Albert CM. Smoking, smoking cessation, and risk of sudden cardiac death in women. *Circulation: Arrhythmia and Electrophysiology*. 2012. ePub ahead of print: <http://circep.ahajournals.org/content/early/2012/11/16/CIRCEP.112.975219.abstract>
21. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: Impact on 6-month survival. *JAMA*. 1993. 270(15):1819-1825.
22. McSweeney JC, Cody M, O'Sullivan P, Elbersen K, Moser DK, Garvin BJ. Women's early warning symptoms of acute myocardial infarction. *Circulation*. 2003;108:2619-2623.
23. http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_women_heart.htm

Promoting Cardiovascular Health by Kathryn Boling, M.D.

1. Laslett LJ, Alagona P Jr, Clark BA 3rd, Drozda JP Jr, Saldivar F, Wilson SR, Poe C, Hart M; The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. *J Am Coll Cardiol*. 2012;60(25 Suppl):S1.
2. Silverstein, Alvin, et. al. 2006. *Heart Disease: Twenty-First Century Medical Library*. Breckenridge, CO: Twenty-First Century Books.
3. S Jousilahti P, Vartiainen E, Tuomilehto J, Puska P; Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. *AU, Circulation*. 1999;99(9):1165.
4. Savji N, Rockman CB, Skolnick AH, Guo Y, Adelman MA, Riles T, Berger JS Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. *J Am Coll Cardiol*. 2013;61(16):17

5. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson P; Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. *JAMA*. 2003;290(7):891.
6. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004;364(9438):937.
7. Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, Gillespie C, Merritt R, Hu FB Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. *JAMA*. 2012 Mar;307(12):1273-83. Epub 2012 Mar 16.
8. Tofler GH, Muller JE; Triggering of acute cardiovascular disease and potential preventive strategies. *Circulation*. 2006;114(17):1863.